SGLT2 inhibitors
Also written as: SGLT2 — sodium-glucose cotransporter-2
Sodium-glucose cotransporter-2 inhibitors, antidiabetic drugs that have shown cardiovascular benefits in heart failure trials.
Full Definition
SGLT2 inhibitors are a class of antidiabetic medications that block sodium-glucose cotransporter-2 in the proximal tubule of the kidney, leading to glucose excretion in urine. Beyond glycemic control, these drugs have demonstrated significant cardiovascular and renal benefits, particularly in heart failure patients with reduced and preserved ejection fraction. In cardiovascular research, SGLT2 inhibitors are studied for their pleiotropic effects including diuretic properties, metabolic benefits, and direct cardiovascular protection. Key drugs in this class include empagliflozin, dapagliflozin, and canagliflozin.
Usage
Usage note: Specify individual drug names when discussing specific trials or mechanisms.
In Context
- "The SGLT2 inhibitor empagliflozin reduced cardiovascular death and heart failure hospitalization by 25%." — Clinical trial results
- "Inclusion criteria required patients to be on stable SGLT2 inhibitor therapy for at least 30 days." — Study eligibility criteria